All relative you know as depends on how much shares you hold ;)...

First 9 Last

Share
Profile

Follow
AlCp

27,397 Posts.

1781

31/01/23

13:27

Post #: 65976022
Share

Originally posted by fattchoi ↑

And Fattchoi's bold prediction could well come true. According to PD in the conference call, PCK like so many of the highly successful products in those major companies he worked for, has now reached an inflection point. This is the point where PCK will go the way of the likes of Cochlear, Pfizer, etc. After all, PainChek is a sticky product and once FDA is achieved, it will be a real monopoly with a very strong regulatory moat! With a very low churn rate, the PCK business will only grow and grow and grow.

Still looking forward to 2025. It is going to be a bumper year. All in good time.

By the way, looks like our resident pest is forever in love with me. Can't go a few posts here without mentioning me. I believe I must have scarred him mentally for life...LOL! One thing for sure, his IMU is doing so badly now (almost half price since his entry) but I am still laughing all the way because my IMU is still doing more than 5 bags for me. And no matter how well he does in IMU, I will always do better. And that will really eat him alive. And just for that alone, life is so good. Oh what a feeling!

Expand

All relative you know as depends on how much shares you hold
It's not like I haven't been through this big downturn with biotech start-up stock. RAP went done to as low as 4c and I still end up with a nearly 6 figure profit after the Pfizer T/O. All about the technology's market and any limitation and unfortunately PCK isn't that stock.....DYOR.

Last edited by AlCp: 31/01/23

PCK Price at posting: 2.9¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 21 more messages in this thread...

First 9 Last

Add PCK (ASX) to my watchlist

(20min delay)
Last 3.0¢		Change 0.000(0.00%)		Mkt cap ! $50.75M

Open	High	Low	Value	Volume
3.1¢	3.1¢	3.0¢	$4.446K	146.0K

Buyers (Bids)

No.	Vol.	Price($)
8	668046	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	122542	3

View Market Depth

No.	Vol.	Price($)
7	468046	0.030
5	6607448	0.029
1	350000	0.028
4	1228344	0.027
4	1600000	0.026

Price($)	Vol.	No.
0.032	122542	3
0.033	126161	2
0.034	79638	2
0.035	125000	1
0.036	322246	2

Last trade - 14.45pm 07/10/2024 (20 minute delay)

PCK (ASX) Chart

All relative you know as depends on how much shares you hold ;)...

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

All relative you know as depends on how much shares you hold ;)...

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News